You are here
- Home
- Therapy Areas
- Neuroscience
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, with Juvenile Idiopathic Arthritis (JIA).
- Disease
- arthritis
- Drug Name
- neuroscience agents
- Generic Name
- Vimovo
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IV
- Start Date
- Jan 18, 1971
- Study Name
- D1120C00037
- Study Id
- D1120C00037
- ClinicalTrials.gov ID
- NCT01544114
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
